CRIS Stock: Price, Forecast, Financials & AI Analysis

Loading...

Loading chart...

High

0.940

Open

0.910

VWAP

1.00

Vol

113.00K

Mkt Cap

12.00M

Low

0.890

Amount

103.00K

EV/EBITDA(TTM)

--

Total Shares

13.00M

EV

3.00M

EV/OCF(TTM)

--

P/S(TTM)

1.00

Curis, Inc. is a biotechnology company. The Company is focused on the development of emavusertib (CA-4948), an orally available, small molecule inhibitor of Interleukin-1 receptor associated kinase (IRAK4). Emavusertib is undergoing testing in the Phase I/II TakeAim Lymphoma study in patients with relapsed/refractory primary central nervous system lymphoma (PCNSL) in combination with the BTK inhibitor ibrutinib, as a monotherapy in the Phase I/II TakeAim Leukemia study in patients with I/II TakeAim Leukemia study in patients with relapsed/refractory acute myeloid leukemia (AML) and relapsed/refractory high risk myelodysplastic syndrome (hrMDS). The Erivedge, is a commercialized orally administered small molecule Hedgehog signaling pathway antagonist. Its other clinical programs include Fimepinostat and CA-170. CA-170 is an oral small molecule drug candidate that targets V-domain Ig Suppressor of T-cell Activation, or VISTA, and PDL1 immune checkpoint proteins.

Show More

Events Timeline

(ET)

2026-01-07

08:50:00

Curis Signs Securities Purchase Agreement for Up to $80.8M

2025-12-09 (ET)

2025-12-09

08:10:00

Curis Updates Acute Myeloid Leukemia Study Data

2025-11-06 (ET)

2025-11-06

16:02:35

Curis Announces Q3 Earnings Per Share of 49 Cents, Below Consensus Estimate of 60 Cents

2025-07-02 (ET)

2025-07-02

08:34:58

Curis announces $7M registered direct, concurrent private placement

2025-05-06 (ET)

2025-05-06

08:08:41

Curis appoints Ahmed Hamdy as Chief Medical Officer

News

an image of PRnewswire

01-09PRnewswire

Curis Closes $80.8 Million PIPE Financing to Advance Emavusertib Development

an image of Newsfilter

01-09Newsfilter

Curis Closes $80.8 Million PIPE Financing to Advance Cancer Drug Development

an image of Benzinga

Innovative Eyewear Inc Reports 45% Year-over-Year Sales Growth in Q4

an image of Benzinga

UniFirst Corp Reports Mixed Q1 Results, Shares Drop 4%

an image of Newsfilter

01-07Newsfilter

Curis Secures $80.8 Million PIPE Financing to Support R&D Efforts

an image of PRnewswire

01-07PRnewswire

Curis Secures $80.8 Million in PIPE Financing

2 Analyst Rating

Wall Street analysts forecast CRIS stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CRIS is 11.00 USD with a low forecast of 5.00 USD and a high forecast of 17.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

2 Buy

0 Hold

0 Sell

Moderate Buy

Current: 0.000

Low

5.00

Averages

11.00

High

17.00

Current: 0.000

Low

5.00

Averages

11.00

High

17.00

Evercore ISI

Outperform

downgrade

$40 -> $38

AI Analysis

2026-01-05

Reason

Evercore ISI

Price Target

$40 -> $38

AI Analysis

2026-01-05

downgrade

Outperform

Reason

Evercore ISI lowered the firm's price target on Caris Life Sciences to $38 from $40 and keeps an Outperform rating on the shares. Recovering end markets and sector rotation have "set the stage for a 2026 Tools play," the analyst tells investors. In MedTech, the firm's survey work points to healthy procedure and CapEx trends into 2026 and early recovery signs in China support the group, but sector rotation and potential ACA and Medicare changes "have bears watching," the analyst added.

Canaccord

Kyle Mikson

Hold

maintain

$28 -> $30

2025-12-22

Reason

Canaccord

Kyle Mikson

Price Target

$28 -> $30

2025-12-22

maintain

Hold

Reason

Canaccord analyst Kyle Mikson raised the firm's price target on Caris Life Sciences to $30 from $28 and keeps a Hold rating on the shares. The firm previewed its life science tools and diagnostics covereage and believes momentum in the sector which began in the second half of this year, can be maintained in 2026. They beleve Caris Life Sciences could be attractive with continued momentum or a material share price pullback.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for CRIS

Unlock Now

Valuation Metrics

The current forward P/E ratio for Curis Inc (CRIS.O) is -0.74, compared to its 5-year average forward P/E of -4.54. For a more detailed relative valuation and DCF analysis to assess Curis Inc 's fair value, Click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

an image of dotted line Image

N/A

5Y Average PE

-4.54

Current PE

-0.74

Overvalued PE

2.26

Undervalued PE

-11.34

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

an image of dotted line Image

N/A

5Y Average EV/EBITDA

-2.72

Current EV/EBITDA

-0.90

Overvalued EV/EBITDA

2.13

Undervalued EV/EBITDA

-7.56

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

an image of dotted line Image

N/A

5Y Average PS

19.17

Current PS

0.99

Overvalued PS

47.84

Undervalued PS

-9.50

Financials

AI Analysis

Annual

Quarterly

Whales Holding CRIS

Trading Trends

People Also Watch

Frequently Asked Questions

What is Curis Inc (CRIS) stock price today?

The current price of CRIS is 0.9107 USD — it has decreased -0.55 % in the last trading day.

What is Curis Inc (CRIS)'s business?

Curis, Inc. is a biotechnology company. The Company is focused on the development of emavusertib (CA-4948), an orally available, small molecule inhibitor of Interleukin-1 receptor associated kinase (IRAK4). Emavusertib is undergoing testing in the Phase I/II TakeAim Lymphoma study in patients with relapsed/refractory primary central nervous system lymphoma (PCNSL) in combination with the BTK inhibitor ibrutinib, as a monotherapy in the Phase I/II TakeAim Leukemia study in patients with I/II TakeAim Leukemia study in patients with relapsed/refractory acute myeloid leukemia (AML) and relapsed/refractory high risk myelodysplastic syndrome (hrMDS). The Erivedge, is a commercialized orally administered small molecule Hedgehog signaling pathway antagonist. Its other clinical programs include Fimepinostat and CA-170. CA-170 is an oral small molecule drug candidate that targets V-domain Ig Suppressor of T-cell Activation, or VISTA, and PDL1 immune checkpoint proteins.

What is the price predicton of CRIS Stock?

Wall Street analysts forecast CRIS stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CRIS is11.00 USD with a low forecast of 5.00 USD and a high forecast of 17.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

What is Curis Inc (CRIS)'s revenue for the last quarter?

Curis Inc revenue for the last quarter amounts to 3.00M USD, increased 8.36 % YoY.

What is Curis Inc (CRIS)'s earnings per share (EPS) for the last quarter?

Curis Inc. EPS for the last quarter amounts to -0.49 USD, decreased -71.18 % YoY.

How many employees does Curis Inc (CRIS). have?

Curis Inc (CRIS) has 33 emplpoyees as of January 29 2026.

What is Curis Inc (CRIS) market cap?

Today CRIS has the market capitalization of 12.00M USD.